23andMe Bankruptcy: Your DNA is for Sale
23andMe showed the permanent risk of consumer DNA databases: bankruptcy, buyers, breaches, deletion uncertainty, and privacy promises that must survive a sale.
23andMe Bankruptcy: Your DNA is for Sale 23andMe - The genetic testing company that collected 15 million users' DNA data Don't mail your spit to a tech company. That was the advice privacy advocates gave for years. Millions of people did it anyway, drawn by the pitch: find cousins, learn ancestry, get a few health hints. Then 23andMe filed for bankruptcy protection in March 2025. Suddenly the most
intimate dataset a person can hand over was being discussed like an asset class:
customers, samples, traits, research consents, and genetic files wrapped into a
sale process. The Asset Class When a company goes bust, creditors get paid. 23andMe did not just have brand equity and lab equipment. It had the genetic data of 15 million people. The Data: roughly 15 million customer accounts, with genetic and health data attached to many of them.
The Buyer Question: a pharmaceutical company may promise to honor the old privacy policy, but users still have to trust a new owner, a new board, and a new set of business incentives.
The Legal Fight: regulators and state attorneys general argued that genetic data should not move without explicit, informed consent. The Forever Leak You can change your credit card. You can change your password. You cannot
change your DNA. Once this data is leaked or sold, it is compromised for your
entire life. And your children's lives. The 2023 breach already proved the danger. Attackers exposed sensitive profile
and ancestry information for millions of users. Even if a company later says the
core genotype files were not part of a specific incident, the privacy harm is
not theoretical. Genetic services create family-scale exposure: your decision
can reveal information about siblings, parents, children, and relatives who
never agreed to the test. Deletion Is Not A Time Machine After the bankruptcy, many customers rushed to delete accounts. That is still
the right move if you no longer want the service, but deletion is not magic. It may not claw back copies already shared with research partners. It may not
erase de-identified research aggregates. It may not undo breach exposure. And
users have to trust that the deletion pipeline is complete, audited, and
honored during a corporate sale. What Can You Do? Request deletion: Use the account deletion flow and separately request destruction of stored samples if the service offers it. Revoke research consent: Do not assume deleting the account also revokes every optional research permission. Save receipts: Keep screenshots or emails confirming deletion and sample destruction requests. Understand GINA limits: In the US, GINA restricts some health insurance and employment uses, but it does not cover every risk category, including life insurance in many contexts. Warn family: Your DNA is also information about relatives. They deserve to know if their genetic privacy may be affected by your past upload. Biometrics are not usernames. Once shared, they cannot be changed.